Topic:

M&A

Latest Headlines

Latest Headlines

MPI buys out a CRO neighbor to bolster early-stage R&D

MPI Research has acquired fellow Michigan CRO Jasper Clinical Research and Development for an undisclosed sum, a move that will augment the company's offerings in Phase I trials.

Fed up with Allergan obstinance, Valeant CEO says he'd hike bid past $200 a share

Valeant CEO J. Michael Pearson is apparently sick of Allergan's mantra that his hostile bid "grossly undervalues" the company. While the bid is a good one, he contended in a Monday letter to the Botox-maker, Valeant will hike it further if it needs to--past $200 a share, in fact--and it's time for Allergan's board to come around.

Lilly divests U.S. animal health assets to Virbac ahead of Novartis deal

French drugmaker Virbac said Monday it would pick up two products marketed by Novartis Animal Health in the U.S.--the parasiticides Sentinel Flavor Tabs and Sentinel Spectrum--which Eli Lilly has agreed to divest in advance of its acquisition of Novartis's animal products unit. Lilly reached the agreement with Virbac in connection with the U.S. Federal Trade Commission's review of its acquisition of Novartis Animal Health, according to a press release issued by Virbac.

What does Pfizer's $11B buyback mean for the chances of an AstraZeneca bid?

Pfizer's $11 billion share buyback, announced late Thursday, gave investors something to focus on, rather than fretting about whether the company would renew its pursuit of AstraZeneca once the required cooling off period lapses in November. But some of them immediately started worrying about whether the buyback meant it was less likely Pfizer would do a big deal.

Actavis primed for another deal, or two, or maybe three

Allergan, Salix and Omega are all reportedly in Actavis' dealmaking sights, but which will the drugmaker go after? With an active M&A track record and deal veteran Brent Saunders at the helm, some analysts think the company could lock down more than one--but it won't necessarily be easy.

New tax rules won't spook Mylan out of Abbott generics buy

A few potential deals have already caved under the weight of new U.S. tax rules that discourage inversion deals. Not Mylan's. The Pittsburgh-based company is pushing ahead with a $5.3 billion plan to buy a piece of Abbott Laboratories' overseas generics business--with a few edits, of course.

Private equity firm looks to unload sterilization services company for $1.5B

Med merger mania is leaving no stone unturned, even sterilization services. On the heels of Steris's bid for Britain's Synergy Health in another inversion deal, private equity firm GTCR is looking to unload Sterigenics International, another sterilization company, for $1.5 billion, including debt.

Siemens in talks to sell hearing aids biz for $2.6B+

On the heels of Siemens' sale of its healthcare IT and microbiology units, the company is eyeing a sale of its hearing aid unit to private equity firm EQT Partners AB for more than $2.6 billion.

Inovio, MedImmune and Penn unite to fight the flu on DARPA's dime

Inovio Pharmaceuticals, AstraZeneca's MedImmune and the University of Pennsylvania have joined forces to study influenza and antibiotic-resistant bacteria, drawing on $12.2 million in federal funds.

Actavis, Sanofi, Boehringer jockey bids for OTC specialist Omega Pharma

Actavis seems to have a finger in every pie lately when it comes to pharma M&A, and rumor has it Omega Pharma's sales process is no exception.